Introduction: Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that infects over 90% of the global population and is etiologically associated with a variety of human neoplasms, including nasopharyngeal carcinoma (NPC) and gastric cancer (GC). Among the most studied regions of the EBV genome is latent membrane protein 1 (LMP1), recognized for its crucial role in cell transformation, immune modulation, and oncogenesis. Investigating the genetic variability of this region may provide insights into the pathogenic mechanisms of the virus and contribute to the molecular surveillance of circulating strains, especially in high-incidence areas such as northern Brazil. Objectives: To analyze the genetic diversity and evolutionary relationships of complete LMP1 region sequences of EBV isolated from oncology patients. Methodology: This is an analytical study involving 26 adult patients diagnosed with NPC and GC between July 2023 and August 2024. Clinical care was provided at João de Barros Barreto University Hospital and Ophir Loyola Hospital, both located in Belém, Pará. Clinical samples were collected using oropharyngeal swabs, and DNA was extracted using the Extracta 96 system. EBV detection was performed using real-time polymerase chain reaction (qPCR). The LMP1 region was sequenced using the Sanger method. Phylogenetic analysis was conducted using IQ-TREE software version 2.2.0, applying the maximum likelihood method. The study was approved by the Research Ethics Committee (CAAE: 68356923.4.0000.5634). Results: Phylogenetic analysis revealed substantial genetic diversity in the EBV LMP1 region among the analyzed samples. The resulting tree identified five main clades: Ia, Ib, Ic, IIa, and IIc. Clades Ia and Ib showed greater genetic proximity, while Ic, IIa, and IIc formed more divergent clusters. Notably, sample 55 BF presented an isolated branch, suggesting distinct ancestry. The observed diversity may be associated with differences in viral tropism, immune escape, or oncogenic potential among strains. Conclusions: High genetic variability was identified in the EBV LMP1 region in cancer patients from the state of Pará. The clustering into distinct clades indicates the co-circulation of multiple viral lineages, which may influence clinical outcomes and host-pathogen interactions. These findings reinforce the importance of regional molecular surveillance and highlight the utility of phylogenetic tools for mapping EBV evolution.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
